RIMAN’s Parent Company Announces Sponsored Research Agreement to Advance Araliadiol Using Organ-on-a-Chip Technology
SEOUL, South Korea, April 15, 2026 /PRNewswire/ -- ASK Company, the parent company of RIMAN, has entered into a sponsored research agreement with Mitragotri Laboratory at the Harvard John A. Paulson School of Engineering and Applied Sciences to validate the functionality and effectiveness of its proprietary ingredient, Araliadiol, derived from Giant...
Reach Surgical Receives CE Mark Approval for iREACH IRIS, First Powered Reusable Stapler with Real-Time Firing Curve™ and 90° Articulation
-iREACH IRIS provides real-time, location-specific insight into tissue behaviour along the staple line SINGAPORE, April 15, 2026 /PRNewswire/ -- Reach Surgical, the surgical solutions division of Genesis MedTech, has received CE Mark approval for iREACH IRIS, a next-generation powered stapling platform designed to deliver Real-Time Firing CurveTM and up to 90° articulation during surgery. Unlike conventional powered staplers that...
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients Zero non-conformities demonstrates company's robust quality management system SHANGHAI, April 15, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has successfully achieved ISO 13485:2016 Medical...
SinoUnited Health Attracts International Patients as China Emerges as Global Medical Tourism Destination
SHANGHAI, April 14, 2026 /PRNewswire/ -- From CAR-T Cell Therapy and cardiac interventions to health checkups and dental care, China's medical capabilities have increasingly drawn international patients in recent years—underscoring the country's rising influence in the global healthcare landscape. SinoUnited Health (SUH), a leading private high-quality healthcare provider in Shanghai, is at the forefront of this trend, driving its...
SST001, an α-syn PET tracer from Mabwell’s incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial
SHANGHAI, April 15, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that 18F-FD4 (R&D code: SST001), an α-synuclein (α-syn) targeted PET tracer independently developed by its incubated company SynuSight Biotech, has recently been approved by the National Medical Products Administration (NMPA) to initiate a Phase I clinical trial. The clinical trial...
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix's pivotal IPAX BrIGHT trial, marking the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, an aggressive form of brain cancer. The...
Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds
MELBOURNE, Australia and Indianapolis, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) ("Telix") is pleased to announce that it has successfully priced and upsized its 1.50 per cent convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the "Issuer"), and guaranteed by Telix...
Mexican company Farmacias Similares brings Dr. Simi to Tokyo in Japan debut
A pop-up store is being opened by Farmacias Similares in Shibuya, which is in the heart of Tokyo. TOKYO, April 15, 2026 /PRNewswire/ -- Dressed as a samurai and with his trademark energetic attitude, Dr. Simi—the face of Farmacias Similares— greets curious visitors stopping by the company's pop-up store in central Shibuya, in the heart of Tokyo. Through this, Grupo Por un...
TCI Biotech Returns to Vitafoods Europe 2026 with Five Provocations for the Nutraceutical Industry and a Glimpse of the Future
BARCELONA, Spain, April 14, 2026 /PRNewswire/ -- TCI Biotech, the global CDMO+ leader in health and wellness innovation, will return to Vitafoods Europe 2026 at booth 3F40, Fira Barcelona Gran Via, armed with five bold challenges to the industry's most stubborn pain points. Building on 46 years of scientific leadership and the momentum of last year's rebranded CDMO vision, TCI...
Advances in Parkinson’s Disease Cell Therapy: XellSmart Launches a Multicenter Phase II Clinical Trial Following Encouraging Phase I Results
SUZHOU, China, April 14, 2026 /PRNewswire/ -- In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell Therapy (XS411) for Primary Parkinson's Disease". The trial continues to be led by Beijing Tiantan Hospital affiliated to Capital Medical University — a National Center for Neurological Disorders, and is again...
